ELAN · Elanco Animal Health Incorporated
Price
Snapshot
50 fields · last close| Market Cap | $12.65B |
| P/E | — |
| Float | 493.1M |
| Beta | 1.75 |
| Volatility 30D | 28.8% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 75.0 |
| Price | 23.77 |
| Change | −6.08% |
| Prev Close | 25.31 |
| Open | 25.18 |
| Day Low | 24.62 |
| Day High | 25.45 |
| Avg Vol | 5 |
| Avg $ Vol | $119.3M |
| 52W High | 27.98 |
| 52W Low | 19.40 |
| 52W Pos | 50.9% |
| From High | −15.05% |
| From Low | +22.53% |
| Max DD 1Y | −26.23% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +2.78% |
| SMA 50 | +2.75% |
| SMA 200 | −0.12% |
| RSI (14) | 71.0 |
| Vol 90D | 35.6% |
| Vol 1Y | 42.3% |
| 1Y Range | 19–28 |
| Daily bars | 549 |
| Perf Week | +11.74% |
| Perf Month | +12.59% |
| Perf Quarter | +4.59% |
| Perf Half Y | −3.32% |
| Perf Year | +10.77% |
| Perf YTD | +5.55% |
| Prev Day | −6.08% |
| Clavix | B |
| Debt / Eq | 0.57 |
| Curr Ratio | 2.17 |
| Int Cover | 3.1× |
| FCF Margin | 6.0% |
| Rev Growth | +6.2% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 9 / 14 |
Clavix risk grade
regraded every trading dayELAN grades B, 75.0 of 100. Steadiest on News Sentiment (68), most exposed on Macro Resilience (58, mixed). 2 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 9 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| ELAN | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.75 | 0.37 |
| 30-day realized volatilityannualized, from daily closes | 28.8% | 32.3% |
| Max drawdown, past yearworst peak-to-trough fall | −26.2% | — |
| Typical daily movemedian absolute daily change | 1.43% | — |
| Days beyond ±3%of the last 252 sessions | 54 (21%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ELAN | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.75 | 0.37 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low 57% of 14 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ELAN | |
|---|---|
| 1 week | +11.7% |
| 1 month | +12.6% |
| Year to date | +5.6% |
| 1 year | +10.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ELAN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 22 Jul |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 28 · 2 |
| Directionarticles whose tone is improving vs worsening | 28 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 14 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| ELAN | |
|---|---|
| Revenue growthyear over year | +6.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openThe article reports that Elanco Animal Health (NYSE:ELAN) shares crossed above their 50-day moving average, the stock's average price over the past 50 trading days, and notes an analyst downgrade. It contains no further details, so no specific business development or cause of the price move can be established.
Elanco Animal Health appointed Jamie Preston as executive vice president and chief people officer, effective November 3. Preston succeeds Dave Kinard, who intends to retire at the end of the year, following an extensive search focused on employee engagement, inclusion, well-being and purpose.
Elanco Animal Health (ELAN) appointed Jamie Preston as its new Executive Vice President and Chief People Officer, effective November 3rd. Preston, who has over 20 years of global HR leadership experience, replaces Dave Kinard, who is retiring at year-end.
The article reviews Elanco Animal Health’s valuation following Zenrelia’s commercial progress, noting that the stock returned 154.5% over the past three years and that Zenrelia has treated more than 2 million dogs. It asks whether Elanco’s future cash generation supports its current market price.
MarketBeat reports that 14 analyst firms give Elanco Animal Health an average rating of "Moderate Buy" and an average target price of $29.42. The provided article body is truncated and does not show the full rating breakdown.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals PLC | A- | $15.06B | 15.93 | 0.36 | Compare |
| CORT | Corcept Therapeutics Incorporated | C | $8.56B | 146.78 | 0.61 | Compare |
| VTRS | Viatris Inc. | B+ | $21.86B | — | 0.87 | Compare |
| AXSM | Axsome Therapeutics, Inc. | B | $7.21B | — | 0.84 | Compare |
| MANE | Veradermics, Incorporated | C | $5.70B | — | 0.30 | Compare |
| ZTS | Zoetis Inc | B+ | $32.94B | 12.85 | 0.65 | Compare |
| RPRX | Royalty Pharma PLC | A | $38.94B | 47.38 | 0.38 | Compare |
| BMY | Bristol-Myers Squibb Company | B+ | $131.2B | 13.93 | 0.14 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.